Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

University of Michigan Rogel Cancer Center logo

University of Michigan Rogel Cancer Center

Status and phase

Active, not recruiting
Phase 1


Mantle Cell Lymphoma


Drug: Venetoclax
Drug: Lenalidomide
Drug: Rituximab

Study type


Funder types



HUM00140979 (Other Identifier)
UMCC 2018.005

Details and patient eligibility


The purpose of this study is to determine if giving an experimental drug called venetoclax in combination with lenalidomide and rituximab is safe and effective for treating people with Mantle Cell Lymphoma (MCL).


30 patients




18+ years old


No Healthy Volunteers

Inclusion criteria

  • Age ≥18 years
  • Diagnosis of mantle cell lymphoma (MCL) established by histologic assessment
  • Laboratory, radiographic, physical exam findings and/or symptoms attributable to MCL
  • ECOG Performance Status (Eastern Cooperative Oncology Group Performance Status: an attempt to quantify cancer patients' general well-being and activities of daily life. The score ranges from 0 to 5 where 0 is asymptomatic and 5 is death) less or equal to 2
  • All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® program
  • Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program.
  • Men and Women of childbearing potential on appropriate contraception
  • Adequate organ function
  • Ability to understand and the willingness to sign a written informed consent.
  • Ability to swallow oral capsules/tablets

Exclusion criteria

  • Prior treatment for MCL with chemotherapy
  • Pregnant or breastfeeding women
  • Grade 2 or higher peripheral neuropathy
  • Known history of CNS (Central Nervous System) or leptomeningeal by MCL prior to study enrollment
  • Significant cardiovascular disease
  • Any condition that might significantly impair drug absorption as determined by the investigator
  • Uncontrolled active systemic fungal, bacterial, viral, or other infection, or intravenous anti-infective treatment within 2 weeks before first dose of study drug
  • History of stroke or intracranial hemorrhage within 6 months of 1st dose of study drug
  • Concurrent participation in another clinical trial
  • Subject has received a moderate or strong CYP3A inhibitor or inducer within 1 week prior to treatment initiation.
  • Psychiatric illness or social situations that would limit compliance with study requirements
  • Subject has known positivity to HIV
  • Active infection with Hepatitis B or C virus as determined by a detectable viral load on PCR.
  • Prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to< 2 years.

Trial design

Primary purpose




Interventional model

Single Group Assignment


None (Open label)

30 participants in 1 patient group

Venetoclax, Lenalidomide, Rituximab
Experimental group
Rituximab 375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12 Lenalidomide 10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12. Venetoclax PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12.
Drug: Rituximab
Drug: Lenalidomide
Drug: Venetoclax

Trial contacts and locations



Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems